Empowered Patient Podcast

Marcy Rogers, CEO and Founder, SpineMark is targeting traumatic brain injuries suffered by athletes, kids, seniors and those getting a concussion from an accident or engagement in a military action. Marcy points out this problem is often ignored and currently there are no treatments for concussions except rest.  SpineMark is developing a breakthrough drug that is a nanoparticle inhaled through the nose and delivered directly to the brain to start working on reducing inflammation and hopefully prevent secondary concussion syndrome. #spinemark #concussions #concussion #traumaticbraininjuries SpineMark.com Download the transcript here.

Harrison Brown Co-Founder and CEO, HeadCheck Health wants to make it easy to better identify, diagnose, manage and clear people who have suffered from a concussion to allow them to resume their regular activities.  While sports teams and other organizations have developed a concussion protocol for managing those who suffer from a head injury, most often the rules are not followed. Patients and athletes are often asked if they have suffered a concussion and HeadCheck wants to provide baseline information as well as indicators of those most at risk for suffering another concussion to assist healthcare providers make more informed decisions. @HeadCheckHealth #concussions #concussion #health #digitalhealth #mhealth HeadCheckHealth.com Download the transcript here

Dr. Jay Anders, Chief Medical Officer, Medicomp Systems addresses how COVID-19 has revealed weaknesses in the US healthcare system and the need to address the challenges from the lack of interoperability and accurate point-of-care information. With an eye to the use of artificial intelligence and remembering that the smartest computer in an exam room sits between the physician's ears, Jay sees many opportunities for AI to make patient health data actionable. @medicompsys #COVID19 #AI #DigitalHealth Medicomp.com Download the transcript here.

Chris Bradley, CEO and Co-Founder, Loki Therapeutics talks about a new generation of cancer immune therapy that takes advantage of the body's ability to fight antigens it already recognizes from a previous childhood vaccination. The delivery mechanism uses an attenuated bacteria listeria monocytogenes that colonizes the tumor and triggers the body's immune system through naive T cells. Early data is showing effectiveness for advanced metastatic pancreatic cancer and advanced metastatic ovarian cancer with potential for treating other solid tumors. #LokiTherapeutics #MemoryTCells #immunotherapy #ovariancancer #pancreaticCancer #Cancer LokiTX.com Download the transcript here

Dr. David Mayer, CEO, Patient Safety Movement Foundation is an advocate for awareness of preventable medical harm in healthcare and steps that need to be taken to keep both patients and healthcare workers safe. With a focus on transparency to allow patients to make informed decisions, Dave emphasizes the need to address gaps in quality and safety data. To inform a larger audience about World Patient Safety Day September 17, Dave is virtually walking across the country and has attracted an international team to walk and run with him through the use of the app Charity Miles. @plan4zero  @WalkforPTSafety  #uniteforsafecare UniteForSafeCare.org Download the transcript here.  

Dr. Tim Rodell, Chief Executive Officer, Aethlon Medical brings us up to speed on the work at Aethlon in developing immunotherapeutic technologies using their Hemopurifier to clear a virus as well as exosomes in patients with cancer as blood flows through the nanofibers of the Hemopurifier cartridge. With more recent understanding of the role of exosomes in the spread of cancer, Aethlon is exploring the advantage of adding treatment with Hemopurifier to make more patients respond to Keytruda. With an Investigational Device Exemption (IDE) from the FDA, Aethlon is opening clinical trials on treating COVID-19 with Hemopurifier to remove the SARS-CoV-2 COVID virus from the circulation. @aethlon_medical #immunotherapy #cancer #exosomes #Infectiousdiseases #COVID19 AethlonMedical.com Download the transcript here.

David Hochman, CEO and Founder, Orchestra BioMed is bringing a partnership model to promote healthcare innovation particularly in the field of drug eluting balloons. Their lead product Virtue Sirolimus Angiofusion Balloon (SAB) is delivering an established therapeutic agent in interventional cardiology during balloon angioplasty without needing a stent permanent implant. This unique drug delivery solution encapsulates the drug in a balloon that has no coating and delivers the drug through micropores in the balloon to deliver the intended dose. #CoronaryDisease #Angioplasty #InstentRestenosis #MedTech OrchestraBioMed.com Download the transcript here

Paula Ragan, CEO and President, X4 Pharmaceuticals is developing innovative approaches to treat patients suffering from rare diseases with an initial focus on WHIM syndrome, a rare disease of the immune system that has a basis in a genetic mutation. X4 is also focused on a rare form of lymphoma called Waldenstrom macroglobulinemia, a blood cancer also caused or driven by a gene mutation.  The X4 drug mavorixafor is in capsule form and is a lifelong therapy that revs up the immune system by attaching to white blood cells. #WHIMSyndrome #WHIM #RareGeneticDiseases #mavorixafor #CXCRA #Waldenstrom X4Pharma.com Download the transcript here

Amit Kumar is President and CEO, Anixa Biosciences, a Silicon Valley based biopharmaceutical company focused on the prevention and treatment of cancer and now developing novel treatments for COVID-19. Using high performance computing, molecular modeling and virtual testing techniques, Anixa is focusing exclusively on the genetics and machinery of the virus and developing a new drug from scratch that targets the operation of the virus itself and can be formulated as a pill. Amit discusses the latest developments in Anixa's COVID-19 drug discovery program and the race underway to develop new therapeutics and vaccines. @AnixaBio #COVID19 #coronavirus #COVID19Therapeutics Anixa.com Download the transcript here

Dr. Juan Dominguez-Bendala is Director of Stem Cell Development of Translational Research and Research Associate Professor of Surgery at the UHealth Diabetes Research Institute, Miami Miller School of Medicine. Juan talks about their recent research on the regeneration of the human pancreas using an innovative approach to keeping human pancreatic slices alive for a long time compared to current techniques where cells die quickly. This additional time allows researchers to explore beta cell regeneration in human cells to better understand how to treat type 1 diabetes. @DiabetesResearch #diabetes #type1diabetes #pancreas DiabetesResearch.org Download the transcript here